Accretion Nutraveda Ltd vs Mono Pharmacare Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 04, 2026

Key Highlights

The Latest Trading Price of Accretion Nutraveda Ltd is ₹ 267.5 as of 29 Apr 15:30 . The P/E Ratio of Accretion Nutraveda Ltd is 0 as of March 2023 .The P/E Ratio of Mono Pharmacare Ltd is 0 as of March 2023 . The Market Cap of Accretion Nutraveda Ltd is ₹ 0 crore as of March 2023 .The Market Cap of Mono Pharmacare Ltd is ₹ 0 crore as of March 2023 . The Dividend Payout of Accretion Nutraveda Ltd is 0 % as of March 2023 .The Dividend Payout of Mono Pharmacare Ltd is 0 % as of March 2023.

About Accretion Nutraveda Ltd

Accretion Nutraveda Limited was initially incorporated as a Private Limited Company on March 16, 2021 and has subsequently, converted the status into a Public Limited Company vide Certificate of Incorporation issued by the Registrar of Companies, Central Processing Centre w.e.f.
May 2, 2025. The Company, established at Ahmedabad, is a healthcare-focused Contract Development and Manufacturing Organization (CDMO), offering specialized services to a diverse range of clients across the various industries.
It specialize in ayurvedic and nutraceutical products including Tablets, Capsules, Oral Liquids, Oral Powders, External Preparation and Oils.
Apart from these, it offer a diverse range of dosage forms, leveraging both Classical Ayurvedic principles and modern nutraceutical science. The products include Tablets, such as film-coated and chewable varieties, for applications in liver care, gynecological care, bone and joint health, and respiratory support.

About Mono Pharmacare Ltd

Mono Pharmacare Limited was originally formed as a Partnership Firm in the name and style of 'M/s.
Mono Chemist' through Partnership Deed dated May 06, 1994.
The Partnership Firm was then converted into Public Limited company in the name of Mono Pharmacare Limited vide Certificate of Incorporation dated October 17, 2022, was issued by the Registrar of Companies, Ahmedabad.
The Company is engaged in the business of marketing and distribution of pharmaceutical products. The product portfolio comprises of a wide range of drugs like Antibiotics, Antifungal, Anti CoughCold & Anti-allergic, Antacid and Antiemetics, Analgesics and Antipyretics, Nutraceuticals, Skincare, Antiseptic, Cardiac and Diabetic & Cosmetics etc. getting products manufactured through contract manufacturing. Supal Distributors LLP, a Partnership Firm, was incorporated on November 24, 2016, with the Promoters of Company, Panilam Lakhatariya and Supal Lakhatariya, being the Original Partners.

FAQs for the comparison of Accretion Nutraveda Ltd and Mono Pharmacare Ltd

Which company has a larger market capitalization, Accretion Nutraveda Ltd or Mono Pharmacare Ltd?

Market cap of Accretion Nutraveda Ltd is 193 Cr while Market cap of Mono Pharmacare Ltd is 23 Cr

What are the key factors driving the stock performance of Accretion Nutraveda Ltd and Mono Pharmacare Ltd?

The stock performance of Accretion Nutraveda Ltd and Mono Pharmacare Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Accretion Nutraveda Ltd and Mono Pharmacare Ltd?

As of May 4, 2026, the Accretion Nutraveda Ltd stock price is INR ₹267.5. On the other hand, Mono Pharmacare Ltd stock price is INR ₹13.25.

How do dividend payouts of Accretion Nutraveda Ltd and Mono Pharmacare Ltd compare?

To compare the dividend payouts of Accretion Nutraveda Ltd and Mono Pharmacare Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.